Trial Profile
A Phase II Study of Bevacizumab Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 13 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2013 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.